Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31165772 | 1.00 | CYP1A2 (0.45) | CYP1A2TDP1CYP2A6NCF1MAPT | |
| SCHEMBL901849 | 0.77 | ALDH1A1 (0.42) | CYP1A2TDP1CYP2A6MAPTL3MBTL1 | |
| SCHEMBL29751038 | 0.77 | ALDH1A1 (0.42) | CYP1A2TDP1CYP2A6MAPTL3MBTL1 | |
| SCHEMBL30133425 | 0.77 | ALDH1A1 (0.42) | CYP1A2TDP1CYP2A6MAPTL3MBTL1 | |
| SCHEMBL637928 | 0.77 | CYP2A6 (0.50) | CYP1A2CYP2A6NCF1MAPTL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL13730044 | 0.76 | CYP2A6 (0.48) | CYP1A2CYP2A6NCF1MAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL28363251 | 0.76 | MAPT (0.50) | CYP1A2CYP2A6NCF1MAPTL3MBTL1 | |
| SCHEMBL539154 | 0.74 | CYP1A2 (0.45) | CYP1A2CYP2A6NCF1MAPTL3MBTL1 | |
| SCHEMBL637927 | 0.74 | CYP1A2 (0.45) | CYP1A2TDP1CYP2A6NCF1MAPT | |
| SCHEMBL305348 | 0.74 | CYP1A2 (0.40) | CYP1A2TDP1CYP2A6MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922407-A | Respiratory Syncytial Virus(RSV) inhibitor | 美迪维尔公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107108626-A | The purposes of azoles and naphthalene compound, the composition comprising these compounds and its controlling invertebrate pests | 巴斯夫欧洲公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-107072985-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-102459272-B | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH INC | 2014-08-06 | — | — | CN | disclosed |
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-7659298-B2 | 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-02-09 | — | — | US | disclosed |
| US-7659298-B2 | 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-02-09 | — | — | US | disclosed |
| WO-2008099021-A1 | DIBENZODIAZEPINONES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| WO-2005060959-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CYP1A2 846/4885TDP1 4727/4885CYP2A6 1230/4885 |
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CYP1A2 846/4885TDP1 4727/4885CYP2A6 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.